CD10, CD34 and Ki67 Immunohistochemical Markers Expression in Endometriosis and Adenomyosis

Roxana-Cleopatra Penciu, Liliana Steriu, Silvia Izvoranu, Iulia Postolache, Andrei-Adrian Tica, Diana Mocanu, Oana-Sorina Tica, Vasile Sârbu, Mariana Deacu, Gabriela Izabela Bălţătescu, Irina Tica, Lucian Cristian Petcu, Vlad Tica
In: Revista de Chimie · 2019 · vol. 70(4) , pp. 1323–1327 · doi:10.37358/rc.19.4.7119 · W3002522573
article OA: hybrid CC0 ⤵ 2 in-corpus citations
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study assessed age, symptoms, and CD10, CD34, and Ki67 expression in patients with endometriosis and adenomyosis, finding clinical differences but no significant differences in biomarker expression.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 ⓘ

This study compared 61 surgically treated patients with endometriosis (ovarian, cervical, and cesarean scar) versus 39 with adenomyosis, assessing clinical variables (age, parity, lesion size, admission and chronic symptoms, including infertility and dysmenorrhea) and immunohistochemical expression of CD10, CD34, and Ki67 in formalin-fixed tissue sections. CD10 was positive in all cases, and there were no statistical differences between endometriosis and adenomyosis regarding the expression levels of the studied biomarkers, while endometriosis patients were younger and more often had dysmenorrhea and infertility than adenomyosis patients. The paper’s limitations include that only two patient groups from a single hospital/period were included and that the study reports mainly lack of differences in biomarker expression without broader functional or molecular validation. This paper is centrally about endometriosis and adenomyosis — it evaluates and compares CD10, CD34, and Ki67 immunohistochemical marker expression between the two conditions.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a benign disease represented by existence of endometrial tissue outside the uterine cavity. Considered in the past a type of endometriosis, adenomyosis is, presently, described as a possible different entity, comparative to endometriosis. That is the reason why we decided to study two groups of patients - one with endometriosis and one with adenomyosis - in order to determine if they are one and the same disease. We included all successive patients admitted and surgically treated in the Emergency Clinical Hospital Constanta between 2015-2017, and, after applying the selection criteria, we assessed 61 patients (group 1) diagnosed with endometriosis - ovarian, cervical, caesarian section scar - and 39 patients (group 2) with adenomyosis. We studied all patients in terms of age, parity, lesions� size, admissions� symptoms, chronic symptoms and immunohistochemical markers CD10, CD34, Ki67. We chose there three markers because of their possible relation to endometriosis and because we were unable to find data regarding the comparison of CD34 or Ki67 expression in endometriosis and adenomyosis and because we did not find articles that reported the expression of these three immunohistochemical markers, combined, for either endometriosis or adenomyosis. According to our study, it seems that endometriosis and adenomyosis are different clinically with regard of age and dysmenorrhea, but there was no statistical difference between the studied immunohistochemical biomarkers� expression in samples of patients with endometriosis or adenomyosis.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosisdysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (11)

Cited by (2)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK